Algenpantucel-L Immunotherapy

BIOLOGICAL2 trials

Sponsors

NewLink Genetics Corporation

Conditions

Locally Advanced Malignant NeoplasmPancreatic CancerPancreatic Carcinoma Non-resectable

Phase 2

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

TerminatedNCT02405585

NewLink Genetics CorporationPancreatic Cancer, Pancreatic Carcinoma Non-resectable

Start: 2015-04-30End: 2016-07-30Updated: 2020-05-28

Phase 3

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

TerminatedNCT01836432

NewLink Genetics CorporationLocally Advanced Malignant Neoplasm, Pancreatic Cancer, Pancreatic Carcinoma Non-resectable

Start: 2013-05-31End: 2017-03-24Updated: 2020-05-28

Related Papers

A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Annals of Surgery2020-12-2284 citations